Skip to main content
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa

Retrospective study in French THIN database

Diagn

Dr. John Cush RheumNow

2 years 2 months ago
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa Retrospective study in French THIN database Diagnostic delay remains common Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain #EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar

Dr. John Cush RheumNow

2 years 2 months ago
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Proportion of ILD patients on IS drugs has massively increased over time!

Also good to see practices are changing &

Dr. John Cush RheumNow

2 years 2 months ago
Proportion of ILD patients on IS drugs has massively increased over time! Also good to see practices are changing & MTX is slowly creeping in Anna Maria Hoffmann-Vold, ILD management session #EULAR2024 @AurelieRheumo https://t.co/npa8O7g7l8
PMR has distinct patterns on MRI shoulder, possibly helping Dx.
#EULAR2024 OP0248 @drdavidliew
also
@bmj_rmdopen
http

Dr. John Cush RheumNow

2 years 2 months ago
PMR has distinct patterns on MRI shoulder, possibly helping Dx. #EULAR2024 OP0248 @drdavidliew also @bmj_rmdopen https://t.co/0J3xUmb9yt where they say: "Similar to our prior findings... the target of inflammation in PMR is the outer covering of a tendon, the peritendineum" https://t.co/AzWkg3z2vR
How good are we at picking up depression in RA patients?
In this Polish registry:
- 1.8% had depression diagnosis
- 21%

Dr. John Cush RheumNow

2 years 2 months ago
How good are we at picking up depression in RA patients? In this Polish registry: - 1.8% had depression diagnosis - 21% had low mood on HAQ & depression has real correlates with disease activity. Plenty to think about with truly holistic RA care! #EULAR2024 POS1045 @drdavidliew https://t.co/ArfqHCKxhz
Difficult-to-treat RA: are we any closer to predicting who is at risk?

4 years ago EULAR published its definition of D

Dr. John Cush RheumNow

2 years 2 months ago
Difficult-to-treat RA: are we any closer to predicting who is at risk? 4 years ago EULAR published its definition of D2T RA. This marked a formal recognition of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic. https://t.co/kQJeUiRNtY https://t.co/xJEVihBMfm
EULAR 2024 – Day 3 Report

We are sharing a few of our favorite abstracts and presentations from today, day 3 in Vien

Dr. John Cush RheumNow

2 years 2 months ago
EULAR 2024 – Day 3 Report We are sharing a few of our favorite abstracts and presentations from today, day 3 in Vienna. https://t.co/XgceAQFVQC https://t.co/80jrjv6Awn
PsA Treatment: is Earlier Better?

Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austr

Dr. John Cush RheumNow

2 years 2 months ago
PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. https://t.co/l2M19PwhzP https://t.co/f3TGBVszU4
As we have incorporated technology into our workflows, and consequently saved lives and suffering, we have balanced our excitement about progress with proof that incremental advances can truly deliver benefit. it is easy to let promise carry our caution away - and while most of the time such advances come in a vetted package, which we can consume without concern, conference abstracts come raw. This is the necessary ingredient to a platform
In a very interesting study at #EULAR2024, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for individuals with axial spondyloarthritis (axSpA) and severe functional limitations. This finding marks a critical advancement in the treatment of axSpA, particularly for patients with sustained disease activity, severe ankylosis, or significant comorbidities, who have
Treat to Target Outcomes in Early AxSpA

Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, A

Dr. John Cush RheumNow

2 years 2 months ago
Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. https://t.co/1svlH2GW9W https://t.co/oT1ZOPdR8e
A Step Closer to Identifying Phenotypes of RA ILD

Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024

Dr. John Cush RheumNow

2 years 2 months ago
A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. https://t.co/VUfsi3HnAA https://t.co/RA9kuuJSUS
JAK Inhibitors for New Indications

Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2

Dr. John Cush RheumNow

2 years 2 months ago
JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. https://t.co/G96x5UMZOX https://t.co/4cOuIbcHVt
×